Biotech stocks led a broad rally in Monday’s session, with several companies surging on company-specific updates ranging from corporate actions tied to Nasdaq compliance to clinical and regulatory milestones. Zhengye Biotechnology jumped more than 1,000% after receiving a Nasdaq non-compliance notice, while Armata Pharmaceuticals advanced on progress toward a planned Phase 3 trial of its lead bacteriophage therapy candidate. Other winners included Advanced Biomed, after it withdrew a planned U.S. securities offering, and Neuronetics, following the appointment of a new chief financial officer.
Key takeaways
- Zhengye Biotechnology surged more than 1,000% as the company disclosed it received a notice related to Nasdaq’s minimum bid price requirement.
- Advanced Biomed gained about 77% after withdrawing its planned U.S. securities offering, easing potential dilution concerns.
- Armata Pharmaceuticals rose about 12% after filing key Phase 3 documentation and completing manufacturing steps tied to a planned trial for AP-SA02.
- Neuronetics climbed over 20% after naming Nir Naor as chief financial officer, with the company still scheduled to report quarterly results in early August.
- Several other large gainers moved without clearly identified news, with reverse stock splits and upcoming reporting dates cited as key nearby developments.
What drove the standout biotech moves
Zhengye Biotechnology Holding Limited was the day’s largest outlier, soaring more than 1,000% to close at $8.01. The jump followed a May 29, 2026 notification that the company was not in compliance with Nasdaq’s minimum bid price requirement under Listing Rules 5550(a)(2). While the notice is specific to listing standards rather than operating performance, the stock’s magnitude suggests investors focused on near-term compliance pathways and the potential for volatility following the communication.
Financial results disclosed earlier this year showed weakening fundamentals: for the fiscal year ended Dec. 31, 2025, the company reported net revenue of RMB116.4 million (US$16.6 million), down 37.6% from RMB186.4 million in fiscal 2024. Net loss was RMB83.0 million (US$11.9 million), compared with net income of RMB13.5 million a year earlier. As of Dec. 31, 2025, the company held cash of RMB50.3 million (US$7.2 million).
Advanced Biomed Inc. rose about 77% to close at $8.90 after it withdrew a planned U.S. securities offering. The company previously filed a registration statement with the SEC on July 23, 2025. It later said it decided not to proceed “at this time” after “careful consideration,” a change investors often interpret as reducing the immediate likelihood of dilution.
The stock’s corporate history also includes a 1-for-20 reverse stock split implemented on Feb. 20, 2026. Advanced Biomed specializes in biomedical technologies for cancer detection and precision medicine, including devices and biochips aimed at screening, diagnosis, treatment selection, and prognosis assessment, with regulatory activity described as in progress in Taiwan and expansion plans for other markets.
Armata Pharmaceuticals Inc. climbed about 12% to $5.06 after reporting progress across clinical, regulatory, and manufacturing activities supporting the initiation of a Phase 3 trial of AP-SA02. The company said it submitted its complete Phase 3 trial protocol and responses to feedback from the FDA following its End-of-Phase 2 meeting. Armata also reported that manufacturing activities required to support the Phase 3 study were completed, and noted the trial is intended to support a future Biologics License Application.
Leadership changes, regulatory timelines and reverse splits
Neuronetics Inc. advanced more than 20% to close at $2.02 after naming Nir Naor as chief financial officer effective July 23, 2026. The appointment is a direct corporate catalyst rather than a clinical update, and the market reaction suggests investors may be looking for execution continuity and financial discipline. Naor most recently served as CFO of Axogen, where the company said profitability and cash flow positivity were achieved within one year and market capitalization tripled.
Neuronetics is scheduled to report Q2, 2026 results during the first week of August. For context, the company projected total revenue growth in the mid-single digits for the second quarter of 2026, with second-quarter 2025 revenue reported at $38.1 million.
Profusa Inc. gained more than 12% to close at $1.95, despite no specific news cited for Monday’s move. Instead, the update points to listing compliance actions: a 1-for-25 reverse stock split took effect on July 7, 2026. The company also reiterated progress toward CE marking for its Lumee Oxygen platform, anticipating that European Notified Body GMED will complete its review in Q3 or early Q4.
Ridgetech Inc. rose about 12% to $1.58 with no specific news mentioned for the day. A 1-for-150 reverse share split for its ordinary shares came into effect on April 8, 2026, and the company is expected to report fiscal year results for the year ended March 31, 2026 later this month. For the prior fiscal year ended March 31, 2025, Ridgetech reported revenue of $119.97 million and net income of $10.20 million, or $1.84 per share.
Turn Therapeutics Inc. moved higher, up more than 10% to close at $10.05, after announcing the completion of a comprehensive interim analysis of an adaptive Phase 2 trial evaluating GX-03 for atopic dermatitis. The company said interim results showed clinically meaningful efficacy across a broader range of disease severity, and that it plans to expand the study to include patients across the full spectrum using the Eczema Area and Severity Index (EASI).
Bigger picture for investors
Across Monday’s winners, the common thread was that catalysts were largely company-specific—often tied to Nasdaq listing compliance actions, capital strategy decisions, and forward clinical or regulatory steps. That mix can lead to sharper short-term moves, especially when investor attention shifts from longer-term trial execution to near-term events such as reverse splits, offering withdrawals, and compliance notifications. The direction of travel for each name remains dependent on follow-through: whether the compliance situations stabilize, whether capital plans remain un-dilutive, and how quickly regulatory work translates into trial start and later milestones.
Investors will likely look next for scheduled reporting dates and upcoming regulatory updates, including Neuronetics’ Q2 results in early August and the timing of fiscal-year updates for companies such as Ridgetech. Additional attention will also fall on Armata’s Phase 3 pathway execution for AP-SA02 and on Turn Therapeutics’ expanded Phase 2 enrollment plans following its interim analysis.
